

Express Mail No.: EV 316175229 US

torney Docket No. LIPO-001/00US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of David FIKSTAD et al.

Serial No.:

10/700,838

Examiner:

Not yet assigned

Confirmation No.: 5766

Art Unit:

1614

Filed:

November 3, 2003

For:

COMPOSITIONS **PHARMACEUTICAL**

WITH

SYNCHRONIZED

SOLUBILIZER RELEASE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08A for the above-identified patent application.

In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.

A return receipt postcard is also enclosed.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 03-3117.

Dated: March 25, 2004

Cooley Godward LLP ATTN: Patent Group Five Palo Alto Square 3000 El Camino Real

Palo Alto, CA 94306-2155

Tel: (650) 843-5000 Fax: (650) 857-0663


Respectfully submitted,

COOLEY GODWARD LLP

By:

Sunil K. Singh Reg. No. 45,298

674021 v1/PA



rney Docket No. LIPO-001/00US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of David FIKSTAD et al.

Serial No.:

10/700,838

Examiner:

Not yet assigned

Confirmation No.: 5766

Art Unit:

1614

Filed:

November 3, 2003

For:

COMPOSITIONS **PHARMACEUTICAL**

WITH

SYNCHRONIZED

SOLUBILIZER RELEASE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed.

This Information Disclosure Statement is filed before the mailing date of a first office action on the merits.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Dated: March 25, 2004

Respectfully submitted, **COOLEY GODWARD LLP**

Cooley Godward LLP ATTN: Patent Group Five Palo Alto Square 3000 El Camino Real Palo Alto, CA 94306-2155

Tel: (650) 843-5000

Fax: (650) 857-0663

By:

Sunil K. Singh Reg. No. 45,298

674019 v1/PA

OIPE	
MAR 2 6 2004 Please type a plus sign (+) inside this box >	+
TRADEMARKET	

Sub	Substitute for form 1449A/PTO				Complete if Known		
540	situte for form 14	177101 1	•	Application Number	10/700,838		
IN	FORMATIO	ON DI	SCLOSURE	Filing Date	November 03, 2003		
ST	FATEMENT	BY A	PPLICANT	First Named Inventor	David FIKSTAD		
				Group Art Unit	1614		
	(use as many s	heets as	s necessary)	Examiner Name	Not yet assigned		
Sheet	1	of	2	Attorney Docket Number	LIPO-001/00US		

	U.S. PATENT DOCUMENTS							
		U.S. Patent Do	cument		Date of Publication of Cited			
Examiner Initials*	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Document MM-DD-YYYY			
	Pl	5,698,155		Grosswald et al.,	12-16-1997			
					-			
	 							
	ļ							
	+							
	ļ <u>.</u>							
		1	<u> </u>					

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	F	oreign Patent Doc	ument	Name of Patentee or Applicant of Cited	Date of Publication	
initiais* No.	No.	Office ³	Number ⁴	Kind Code ⁵ (if known)	Document Document	of Cited Document MM-DD-YYYY	T ⁶
	<u> </u>		. ,				
	 	+					

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number.
 See attached Kinds of U.S. Patent Documents.

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

OIPE	
MAR 2 Planty plus sign (+) inside this box >	+

DEMARKS stitute for form 1449B/PTO					Complete if Known		
				Application Number	10/700,838		
INF	ORMATI	ON DI	SCLOSURE	Filing Date	November 03, 2003		
STATEMENT BY APPLICANT		First Named Inventor	David FIKSTAD				
				Group Art Unit	1614		
(use as many.	sheets as	necessary)	Examiner Name	Not yet assigned		
Sheet	2	of	2	Attorney Docket Number	LIPO-001/00US		

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	D1	LANGER, "New Methods of Drug Delivery," Science (1990) 249: 1527-1533.	
	D2	SAUDEK et al., "A preliminary trial of the programmable implantable medication system for insulin delivery," N. Engl. J. Med. (1989) 321:574-579.	
	D3	SEFTON "Implantable pumps," (1987) CRC Crit. Rev Biomed. Eng 14(3): 201-240.	
	D4	TREAT et al., in "Liposomes in the Therapy of Infectious Disease and Cancer," Lopez-Berestein and Fidler (eds.), Liss, New York, (1989) 353-365.	

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

674012 v1/PA

¹ Unique citation designation number.
² Applicant is to place a check mark here if English language Translation attached.